ASHLEY LINDSEY: Open Payments
NPI 1548563208 · JEFFERSONVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$892 in 68 payments from 10 companies in 2025. Trend: 2023 $597 · 2024 $812 · 2025 $892
Food & beverage: $892
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $295 |
| Alkermes, Inc. | 18 | $191 |
| ABBVIE INC. | 14 | $149 |
| Axsome Therapeutics, Inc. | 9 | $138 |
| Lundbeck LLC | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Tris Pharma Inc | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, LYBALVI, Auvelity, ARISTADA, REXULTI, FANAPT, INGREZZA.
Industry payments across IN — which companies pay providers there.
